[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
Oct 2011

Successful Long-term Use of Intravenous Immunoglobulin to Treat Livedoid Vasculopathy Associated With Plasminogen Activator Inhibitor-1 Promoter Homozygosity

Author Affiliations

Author Affiliations: Department of Dermatology, University of Maryland, Baltimore (Drs Tuchinda, Tammaro, and Gaspari); Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand (Dr Tuchinda); and Department of Dermatology, University la Sapienza, Rome, Italy (Dr Tammaro).

Arch Dermatol. 2011;147(10):1224-1225. doi:10.1001/archdermatol.2011.274

We previously reported the case of a 33-year-old woman who was diagnosed as having livedoid vasculopathy (LV) associated with plasminogen activator inhibitor-1 (PAI-1) promoter homozygosity (4G/4G).1 In patients with homozygosity for the 4G allele, high levels of PAI-1 may be associated with increased risk of venous thromboembolism, coronary disease, and poor outcome of stroke.1 This patient was successfully treated with infusions of tissue plasminogen activator (tPA) (10 mg/d for 2 weeks) after failed treatments with anti-inflammatory and antiplatelet therapies.

First Page Preview View Large
First page PDF preview
First page PDF preview
×